Nanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement

Bulletin Express

Oct 17

Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second announcement, posted at 10:36 p.m. on the “HKEX news” website, includes additional information not found in the earlier version posted at 8:48 p.m.

The second announcement clarifies that the agreement includes an upfront payment of US$20 million, plus US$5 million in the fourth quarter of 2025, along with potential near-term milestone payments of up to US$13 million. The company stated this added detail was to enhance transparency by providing more information on potential near-term milestone payments. As a result, the revised announcement supersedes the earlier version.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1185591939"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185591939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185591939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185591939","market":"hk","top_or_hot":-1,"title":"Nanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second announcement, posted at 10:36 p.m. on the “HKEX news” website, includes additional information not found in the earlier version posted at 8:48 p.m.</p>\n<p>The second announcement clarifies that the agreement includes an upfront payment of US$20 million, plus US$5 million in the fourth quarter of 2025, along with potential near-term milestone payments of up to US$13 million. The company stated this added detail was to enhance transparency by providing more information on potential near-term milestone payments. As a result, the revised announcement supersedes the earlier version.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-17 17:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second announcement, posted at 10:36 p.m. on the “HKEX news” website, includes additional information not found in the earlier version posted at 8:48 p.m.</p>\n<p>The second announcement clarifies that the agreement includes an upfront payment of US$20 million, plus US$5 million in the fourth quarter of 2025, along with potential near-term milestone payments of up to US$13 million. The company stated this added detail was to enhance transparency by providing more information on potential near-term milestone payments. As a result, the revised announcement supersedes the earlier version.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1185591939","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185591939","pubTimestamp":1760693480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"南京先导生物(9887)就许可协议公告发布澄清","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second announcement, posted at 10:36 p.m. on the “HKEX news” website, includes additional information not found in the earlier version posted at 8:48 p.m.\nThe second announcement clarifies that the agreement includes an upfront payment of US$20 million, plus US$5 million in the fourth quarter of 2025, along with potential near-term milestone payments of up to US$13 million. The company stated this added detail was to enhance transparency by providing more information on potential near-term milestone payments. As a result, the revised announcement supersedes the earlier version.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}